Cytovale Is A Medical Diagnostics Company Based In San Franciscofounded In 2013The Company Specializes In Developing Rapid Diagnostic Technologies Aimed At Improving The Early Detection Of Life Threatening Conditionsparticularly Sepsiswith Significant Backing From Venture Capital Firmscytovale Has Raised $100 Million In Series D Funding To Support Its Commercialization Efforts In The U Sset For 2025 Cytovale S Flagship Productintellisepa Is An Fda Cleared Rapid Sepsis Detection System Designed For Emergency Departmentsit Utilizes Machine Learningmicrofluidicsand Deformability Cytometry To Analyze White Blood Cell Behavior In Response To Infectiondelivering Results In About 8 Minutesthe Technology Has Been Evaluated In Over 15 000 Patientsdemonstrating Significant Cost Savings And Earning Recognition For Its Clinical Impactthe Company Aims To Expand Its Presence In Multiple States And Health Systemsfocusing On Enhancing Diagnostic Accuracy And Addressing The Substantial Healthcare Burden Posed By Sepsis
